Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.275 -0.045 (-3.41%)
Streaming Delayed Price Updated: 3:34 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LAVA Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
From LAVA Therapeutics N.V.
Via GlobeNewswire
Recap: LAVA Therapeutics Q1 Earnings
Via Benzinga
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space
Via Benzinga
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
Why Lululemon Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Gainers Better Choice Company Inc. (NASDAQ: BTTR) shares rose 37% to $0.4522 in pre-market trading. Better Choice said it has selected Re:Amaze to assist in customer retention and acquisition for its... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for a dive into the biggest pre-market stock movers for Friday as we check out the winners and losers this morning! 
Via InvestorPlace
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Announces Annual Meeting of Shareholders
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Appointment of New Directors to the Board
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board 
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. 
Via Benzinga
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts 
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
From LAVA Therapeutics N.V.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
Upgrades 
Via Benzinga
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
From LAVA Therapeutics N.V.
Via GlobeNewswire
Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday
Piper Sandler raised Snap Inc. (NYSE: SNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday. 
Via Benzinga
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.